Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan

• Main Authors: Gulbanu Sarsenbayeva (Author), Timur Issagulov (Author), Markhabat Kassenov (Author), Ruslan Abitay (Author), Mukhit Orynbayev (Author), Marina Stukova (Author), Maria Pisareva (Author), Timur Davlyatshin (Author), Kutumbetov Lespek (Author), Berik Khairullin (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background The study was aimed at comparative evaluation of seasonal influenza vaccine RIBSP versus commercial vaccine VAXIGRIP® for immunogenicity and safety in the course of clinical trial phase II on healthy subjects up to 60 years. Methods The trial involved 150 subjects in randomized 2:1 groups...